Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators

Antimicrob Agents Chemother. 2015 Nov 9;60(1):689-92. doi: 10.1128/AAC.02000-15. Print 2016 Jan.

Abstract

We determined the in vitro activity of SMT19969 and 11 comparators, including metronidazole, vancomycin, and fidaxomicin, against 107 C. difficile isolates of different antimicrobial resistance phenotypes. Fidaxomicin and SMT19969 were the most active. The fidaxomicin and SMT19969 geometric mean MICs were highest in ribotypes known to show multiple resistance. Coresistance to linezolid and moxifloxacin was evident in ribotypes 001, 017, 027, and 356. The high-level ceftriaxone resistance in ribotypes 356 and 018 was location linked.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminoglycosides / pharmacology
  • Anti-Bacterial Agents / pharmacology*
  • Benzimidazoles / pharmacology*
  • Ceftriaxone / pharmacology
  • Clostridioides difficile / drug effects*
  • Clostridioides difficile / genetics
  • Clostridioides difficile / isolation & purification
  • Clostridium Infections / drug therapy
  • Clostridium Infections / microbiology
  • Drug Resistance, Multiple, Bacterial*
  • Fidaxomicin
  • Fluoroquinolones / pharmacology
  • Humans
  • Linezolid / pharmacology
  • Metronidazole / pharmacology
  • Microbial Sensitivity Tests
  • Moxifloxacin
  • Phenotype*
  • Pyridines / pharmacology*
  • Ribotyping
  • Vancomycin / pharmacology

Substances

  • Aminoglycosides
  • Anti-Bacterial Agents
  • Benzimidazoles
  • Fluoroquinolones
  • Pyridines
  • ridinilazole
  • Metronidazole
  • Vancomycin
  • Ceftriaxone
  • Linezolid
  • Moxifloxacin
  • Fidaxomicin

Grants and funding

Richard Vickers is an employee of Summit plc and was involved in study design and manuscript preparation.